IN8bio (IN8bio) Price-to-Tangible-Book : 3.04 (As of Jun. 05, 2024)

View and export this data going back to 2021. Start your Free Trial

What is IN8bio Price-to-Tangible-Book?

As of today (2024-06-05), IN8bio's share price is $1.23. IN8bio's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $0.41. Hence, IN8bio's Price to Tangible Book Ratio of today is 3.04.

The historical rank and industry rank for IN8bio's Price-to-Tangible-Book or its related term are showing as below:

INAB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.6 Med: 2.16 Max: 3.24
Current: 3

During the past 6 years, IN8bio's highest Price to Tangible Book Ratio was 3.24. The lowest was 1.60. And the median was 2.16.

INAB's Price-to-Tangible-Book is ranked worse than
52.91% of 1221 companies
in the Biotechnology industry
Industry Median: 2.78 vs INAB: 3.00

A closely related ratio is called PB Ratio. As of today, IN8bio's share price is $1.23. IN8bio's Book Value per Sharefor the quarter that ended in Mar. 2024 was $0.41. Hence, IN8bio's P/B Ratio of today is 3.04.

IN8bio Price-to-Tangible-Book Historical Data

The historical data trend for IN8bio's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IN8bio Price-to-Tangible-Book Chart

IN8bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

2.16

2.51

2.40

IN8bio Quarterly Data
	Dec18	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Price-to-Tangible-Book	Get a 7-Day Free Trial															1.93	2.16	1.87	2.40	2.91

Competitive Comparison of IN8bio's Price-to-Tangible-Book

For the Biotechnology subindustry, IN8bio's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IN8bio's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IN8bio's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where IN8bio's Price-to-Tangible-Book falls into.

IN8bio Price-to-Tangible-Book Calculation

IN8bio's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2024 )
	=	1.23	/	0.405
	=	3.04

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

IN8bio Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of IN8bio's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

IN8bio (IN8bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IN8bio Inc (NAS:INAB) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

6JH:Germany

Address

350 5th Avenue, Suite 5330, New York, NY, USA, 10118

Website

https://www.in8bio.com

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.

Executives

Jeremy R. Graff	director	C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Patrick Mccall	officer: Chief Financial Officer	C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
William Tai-wei Ho	director, officer: President, CEO and CFO	C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Fund Ii, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Leslie W. Kreis	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Fletcher Aaron G.l.	director, 10 percent owner	40 GUEST STREET, BOSTON MA 02135
Transcend Partners Opportunity Fund Llc	10 percent owner	10 ORINDA VIEW ROAD, ORINDA CA 94563
Lawrence Lamb	officer: EVP and CSO	C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Incysus Co-invest I, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Trishna Goswami	officer: Chief Medical Officer	C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Kate Rochlin	officer: Chief Operating Officer	IN8BIO, INC., EMPIRE STATE BUILDING, SUITE 5330, NEW YORK NY 10118